Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

New Damages Trial for Wyeth in Arkansas Hormones Case

By Pharmaceutical Processing | November 3, 2009

TOM PARSONS Associated Press Writer LITTLE ROCK, Ark. (AP) — Wyeth Pharmaceuticals will get a new trial to determine if the drugmaker should pay punitive damages to a woman who got breast cancer after taking hormone replacement therapy, a federal appeals court ruled Monday. The 8th U.S. Circuit Court of Appeals in St. Louis ruled on an appeal by the woman, who sued Wyeth and drugmaker Upjohn Co., and an appeal by the two companies. An Arkansas jury had sided with Donna Scroggin in her lawsuit against Wyeth and Upjohn, awarding her $2.75 million in compensatory damages and $27 million in punitive damages in February 2008. Jurors concluded Wyeth inadequately warned the Little Rock woman that its drugs Premarin and Prempro carried an increased risk of breast cancer. The suit also involved Upjohn’s Provera, an estrogen-only drug. U.S. District Judge Bill Wilson struck down the punitive damages award in July 2008, saying certain testimony from former Food and Drug Administration official Dr. Suzanne Parisian, who was the plaintiff’s regulatory expert, shouldn’t have been allowed at trial. Monday’s ruling by a three-judge panel of the appeals court upheld the jury’s compensatory damage award, but also upheld Wilson’s decision that Upjohn should not have to pay punitive damages. However, the appeals court said a new trial must be held to determine if Wyeth should pay them. “Scroggin presented sufficient evidence to submit the question of punitive damages (against Wyeth) to the jury, even without” the testimony from Scroggin’s expert, the appeals decision said. The appeals court said Wilson analyzed the punitive-damages evidence against Wyeth on a piece-by-piece basis, “explaining that each piece failed to present clear and convincing evidence of reckless indifference.” “This individualized treatment of the evidence may inadvertently have obscured the full scope of Wyeth’s conduct that the evidence collectively portrayed,” the appeals court decision said. “A jury could reasonably construe Wyeth’s documents as repeated efforts over many years to undermine information and studies that attempted to show a breast-cancer link.” Both Wyeth, based at Madison, N.J., and Upjohn are now part of New York-based pharmaceutical giant Pfizer Inc. A man who answered the telephone at Wyeth after business hours Monday said no one was available to comment on the appeals court’s ruling. A telephone number was not listed for Scroggin in Little Rock.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards